USFDA & biotechHigh importanceAug 28 · 09:00 KST
We show only the direction of market expectations, not consensus figures. For reference only; not investment advice.
HMPL-523 FDA review: a US FDA-related date, scheduled for Aug 28, 2026 at 09:00 KST. The review outcome and details are confirmed by the company’s official announcements and FDA notices.
FDA dates for biotech companies (approval reviews, advisory committees and so on) tend to be followed by larger moves in the related shares, depending on the outcome. This page provides schedule facts for reference only; it is not a prediction.
HMPL-523 FDA review: a US FDA review or announcement date. It is scheduled for Aug 28, 2026.
In the company’s official announcements (press releases, SEC filings) and FDA notices.
Approval and review outcomes can change how the company’s business is assessed, so related shares tend to be more volatile around the announcement (for reference only; not a prediction).
